First human tests: how does a failing liver handle a new drug?
NCT ID NCT07486102
Summary
This early-stage study aims to understand how a new medicine, BI 3000202, is processed by the body in people with and without liver problems. It will enroll 44 adults, including healthy volunteers and people with varying degrees of liver impairment. Each participant takes a single tablet, and researchers will closely monitor drug levels in the blood and check for side effects over about one month.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
American Research Corporation at the Texas Liver Institute
San Antonio, Texas, 78215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.